---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-001635"
form_type: "8-K"
ticker: "SNOA"
cik: "0001367083"
company_name: "Sonoma Pharmaceuticals, Inc."
filed_at: "2024-03-22T23:59:59+00:00"
generated_at: "2026-06-04T08:59:52.975182+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Nasdaq grants Sonoma Pharmaceuticals 180-day extension to meet $1.00 bid price rule

## Summary
- Company received until September 16, 2024 to regain compliance with Nasdaq minimum $1.00 closing bid price rule.
- Initial compliance deadline of March 20, 2024 was not met; deficiency first disclosed in September 2023.
- If bid price closes at $1.00+ for 10 consecutive business days before Sept 16, Nasdaq will confirm compliance.
- Failure to cure by Sept 16 could lead to delisting; company may appeal or consider reverse stock split.

## SEC filing metadata
- accession: 0001683168-24-001635
- form_type: 8-K
- ticker: SNOA
- cik: 0001367083
- company_name: Sonoma Pharmaceuticals, Inc.
- filed_at: 2024-03-22T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367083/000168316824001635/0001683168-24-001635-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367083/000168316824001635/sonoma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-001635
- JSON: https://secwatch.observer/filing/0001683168-24-001635.json
- Plain text: https://secwatch.observer/filing/0001683168-24-001635.txt

## Key facts
- Listing & Compliance Notices
  Sonoma Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: March 21, 2024, Sonoma Pharmaceuticals, Inc. (the “Company”) received a notice (the “Extension Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until September 16, 2024 to regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2) (the “Rule”). The Extension Notice has no immediate effect on the listing of the Company’s common stock. As previously disclosed in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367083/000168316824001635/0001683168-24-001635-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.